Cilta-cel for RRMM after 1–3 prior LOT: Long-term results from CARTITUDE-2

Long-term follow-up results from Cohort A of the phase II CARTITUDE-2 study (NCT04133636) evaluating ciltacabtagene autoleucel (cilta-cel) in 20 patients with relapsed/refractory multiple myeloma (RRMM) who had received 1–3 prior lines of therapy (LOT), including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), and had lenalidomide-refractory disease, were presented by Adam Cohen at the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK.

Key data: At a median follow-up of 60.7 months, 50% of patients remained alive and progression-free for ≥5 years without further antimyeloma treatment. Median progression-free survival (PFS) was 60.5 months and median overall survival (OS) was not reached (NR); 5-year PFS and OS rates were 54.2% and 69.2%, respectively. Patients who remained alive and progression-free for ≥5 years had higher levels of CD4+ naïve T cells at apheresis (p = 0.036) and chimeric antigen receptor (CAR)+ CD4+ central memory T cells at peak expansion post-infusion (p = 0.019) vs patients with progressive disease (PD) or death due to PD within 5 years. Since the previous CARTITUDE-2 report, five patients had second primary malignancies and two deaths were reported, including one due to an adverse event (AE). No new cases of CAR T-cell-related neurotoxicity were reported.

Key learning: In this long-term analysis of CARTITUDE-2 Cohort A, cilta-cel was associated with durable, treatment-free disease control in patients with RRMM who had received 1–3 prior LOT, with remissions extending beyond 5 years after a single infusion in 50% of patients.